Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Call Transcript

Rosty Raykov: Well, I don’t know if you know much about the history of Fennec, which was [indiscernible] company Adherex, but we started with three, and we have one. So, I think it’s very important for us to establish this one on the market before looking into bringing something else in.

Dipesh Patel: Got it. Okay. And then last question, gentlemen. What does the long-term competitive landscape look like for PEDMARK in the U.S.?

Rosty Raykov: I mean I think the most critical piece is, would cisplatin remain a mainstay treatment in pediatric cancer? And we believe it will be. It’s pediatric tumors in general and AYA tumors in general are very receptive, sensitive to cisplatin. Oncologists see a good use for the drug. They know how to use it. They’ve optimized it. So, anything else that comes usually comes on top of the cisplatin and comes at later stages. So, I don’t see anyone looking to replace cisplatin. So that’s really the view that we have and what we see in the marketplace. So yeah, I don’t expect substitution for cisplatin any time soon.

Dipesh Patel: Got it. Thank you, Rosty and gentlemen, for the update. Appreciate it.

Operator: And I’m not showing any further questions at this time. I’d like to turn the call back over to Rosty for any closing remarks.

Rosty Raykov: Yes. I would like to thank you all for joining us today, and we look forward to updating you on our continued launch progress and corporate milestones in future quarterly calls. Thank you, and have a great day.